Drug discovery is a resource-intensive process riddled with high failure rates. A lack of good preclinical models often results in identified drug candidates showing poor efficacy in human clinical trials. Cells derived from human-induced pluripotent stem cells (hiPSCs) better recapitulate the pathophysiology of human diseases and are quickly becoming the go-to tool for disease modeling and drug testing.
Drug discovery and development are frequently associated with skyrocketing costs, which are often attributed to the high failure rates in the drug discovery process. For instance, 90% of identified drug candidates do not even pass phase I clinical trials. The main reason is the use of preclinical models that do not properly recapitulate human responses to drugs.
Conventionally used preclinical models include animals, such as rats, rabbits, guinea pigs, non-human primates, including monkeys, and chimpanzees, as well as primary human differentiated cells.
Malathi Raman, Senior Product Manager of Stem Cells, Takara Bio Europe
“There is a lack of good preclinical models that accurately predict human drug response,” explained Malathi Raman,
The post How Human-induced Pluripotent Stem Cells are Revolutionizing Drug Discovery appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.